GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » EV-to-FCF

BriaCell Therapeutics (FRA:8BT0) EV-to-FCF : -0.42 (As of Mar. 30, 2025)


View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BriaCell Therapeutics's Enterprise Value is €8.62 Mil. BriaCell Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2025 was €-20.56 Mil. Therefore, BriaCell Therapeutics's EV-to-FCF for today is -0.42.

The historical rank and industry rank for BriaCell Therapeutics's EV-to-FCF or its related term are showing as below:

FRA:8BT0' s EV-to-FCF Range Over the Past 10 Years
Min: -0.44   Med: 0   Max: 0
Current: -0.44

FRA:8BT0's EV-to-FCF is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 3.31 vs FRA:8BT0: -0.44

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-30), BriaCell Therapeutics's stock price is €3.715. BriaCell Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 was €-4.710. Therefore, BriaCell Therapeutics's PE Ratio (TTM) for today is At Loss.


BriaCell Therapeutics EV-to-FCF Historical Data

The historical data trend for BriaCell Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics EV-to-FCF Chart

BriaCell Therapeutics Annual Data
Trend Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.33 -2.71 -4.77 -3.57 -0.51

BriaCell Therapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.94 -1.09 -0.51 -1.05 -0.44

Competitive Comparison of BriaCell Therapeutics's EV-to-FCF

For the Biotechnology subindustry, BriaCell Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's EV-to-FCF falls into.


;
;

BriaCell Therapeutics EV-to-FCF Calculation

BriaCell Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8.617/-20.563
=-0.42

BriaCell Therapeutics's current Enterprise Value is €8.62 Mil.
BriaCell Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-20.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BriaCell Therapeutics  (FRA:8BT0) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BriaCell Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.715/-4.710
=At Loss

BriaCell Therapeutics's share price for today is €3.715.
BriaCell Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.710.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BriaCell Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics Business Description

Traded in Other Exchanges
Address
235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines